Cargando…

A Genetic Approach to the Association Between PCSK9 and Sepsis

IMPORTANCE: Whether the PCSK9 gene is associated with the progress from infection to sepsis is unknown to date. OBJECTIVE: To test the associations between PCSK9 genetic variants, a PCSK9 genetic risk score (GRS), or genetically estimated PCSK9 expression levels and the risk of sepsis among patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, QiPing, Wei, Wei-Qi, Chaugai, Sandip, Carranza Leon, Barbara G., Kawai, Vivian, Carranza Leon, Daniel A., Jiang, Lan, Zhong, Xue, Liu, Ge, Ihegword, Andrea, Shaffer, Christian M., Linton, MacRae F., Chung, Cecilia P., Stein, C. Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739725/ https://www.ncbi.nlm.nih.gov/pubmed/31509211 http://dx.doi.org/10.1001/jamanetworkopen.2019.11130

Ejemplares similares

Association Between Low-Density Lipoprotein Cholesterol Levels and Risk for Sepsis Among Patients Admitted to the Hospital With Infection
por: Feng, QiPing, et al.
Publicado: (2019)

The relationship between high density lipoprotein cholesterol and sepsis: A clinical and genetic approach
por: Liu, Ge, et al.
Publicado: (2023)

Pharmacogenetics of Hypoglycemia Associated with Sulfonylurea Therapy in Usual Clinical Care
por: Mitchell, Sabrina L, et al.
Publicado: (2020)

SUN-573 Use of PCSK9 Inhibitors Post-Transplant
por: Matthews, Juliana, et al.
Publicado: (2020)

Association between APOL1 risk variants and the occurrence of sepsis in Black patients hospitalized with infections: a retrospective cohort study
por: Jiang, Lan, et al.
Publicado: (2023)

A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes
por: Liu, Ge, et al.
Publicado: (2021)

Genome-wide association analyses of common infections in a large practice-based biobank
por: Jiang, Lan, et al.
Publicado: (2022)

PCSK9: A Potential Therapeutic Target for Sepsis
por: Yuan, Yuan, et al.
Publicado: (2020)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
por: Chamberlain, Alanna M., et al.
Publicado: (2019)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records
por: Feng, QiPing, et al.
Publicado: (2018)

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
por: Girona, Josefa, et al.
Publicado: (2016)

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
por: Caselli, Chiara, et al.
Publicado: (2019)

Clinical diagnoses associated with a positive antinuclear antibody test in patients with and without autoimmune disease
por: Zanussi, Jacy T., et al.
Publicado: (2023)

Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
por: Macchi, C., et al.
Publicado: (2020)

Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"
por: Fazio, Sergio, et al.
Publicado: (2001)

CYP2D6 GENOTYPE AND REDUCED CODEINE ANALGESIC EFFECT IN REAL-WORLD CLINICAL PRACTICE
por: Carranza-Leon, Daniel, et al.
Publicado: (2021)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Wang, Yu, et al.
Publicado: (2016)

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
por: Fischer, Laurenz T., et al.
Publicado: (2021)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis
por: Linton, MacRae F., et al.
Publicado: (2019)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
por: Kaya, Esra, et al.
Publicado: (2017)

Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia
por: Eroğlu, Zuhal, et al.
Publicado: (2018)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors
por: Genga, Kelly Roveran, et al.
Publicado: (2018)

Paired Basic Amino Acid-cleaving Enzyme 4 (PCSK6): An Emerging New Target Molecule in Human Melanoma
por: WEISHAUPT, Carsten, et al.
Publicado: (2020)

Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
por: Yang, Sheng-Hua, et al.
Publicado: (2018)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice
por: Anandi, Prathima, et al.
Publicado: (2020)

PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
por: Ferrari, Filipe, et al.
Publicado: (2019)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p2b0vr4e7n1rkcvolqs08cc1is